This was a randomized, double-blind trial designed to prospectively assess the impact of centralized spirometry in 89 patients with mild-to-moderate cystic fibrosis who were being treated with denufosol or placebo. Endpoints included FEV1, FVC and FEF25–75, which were examined using the Vitalograph Spirotrac Centralized Spirometry System.
- Author Goss CH et al.
- Publication Journal of Cystic Fibrosis
- Year 2008
- Device Type Spirotrac
